Ms. Whitaker has been a member of the Board of Directors since December 2013. Since October 2018, she has served as the Chief Executive Officer of Aerami Therapeutics, Inc. (formerly Dance Biopharm Holdings, Inc.), a clinical stage pharmaceutical and medical device company. Ms. Whitaker started her healthcare career in 1991 as a sales representative with The Upjohn Company, now Pfizer, Inc. She subsequently transitioned to GlaxoSmithKline PLC in 1992 where she rose in the leadership ranks to become a member of the global management team as the Global Head of the Leadership and Organization Development Centre of Excellence and ultimately served as the Senior Vice President and Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises from September 2009 to September 2011. Ms. Whitaker joined Sanofi SA in 2011 where she served through August 2014 as the President of the North America Region and CEO of Sanofi US, LLC, where she led more than 5,000 employees to deliver revenues exceeding $16 billion annually. Ms. Whitaker served as the CEO and President of Synta Pharmaceuticals, Inc., an oncology focused late stage pharmaceutical development company, which is now Madrigal Pharmaceuticals, from September 2014 to April 2015. She joined Bausch Healthcare Companies in May 2015 and served through January 2017 as Executive Vice President and Company Group Chairman for the global branded pharmaceutical segment where she notably led the successful integration of two multi-billion dollar businesses, Salix Pharmaceuticals and Dendreon. In 2017, Ms. Whitaker transitioned to the early stage biotech sector and helped build Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, focused on developing therapies to treat people living with severe, chronic respiratory diseases. Prior to joining Aerami, starting in April 2018, Ms. Whitaker served as Managing Partner for Anne Whitaker Group, LLC, a consultant and professional service firm focused primarily on advising biotech and specialty pharmaceutical companies with commercial and product development strategy.
Ms. Whitaker previously served on the board of publicly traded Synta Pharmaceuticals, Inc. (Nasdaq: SNTA), now Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL). Ms. Whitaker is currently an independent director on the board of two additional publicly traded companies, Mallinckrodt, Plc (NYSE: MKN), a specialty pharmaceutical company, and Vectura Group, Plc (London Exchange: VEC-GB), a pharmaceutical and medical device company. She was appointed in 2018 by the Governor of Alabama to serve as a Trustee for the University of North Alabama.